Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

The integration enables closed system processing, a significant step in automating platforms and protocols for cell therapies ...

UBS has downgraded Charles River Laboratories (NYSE:CRL) to neutral from buy, citing concerns about decelerating sales growth ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

Equities research analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, January 15th ...

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...

This was the stock's fourth consecutive day of losses.

Charles River Laboratories International, Inc. today announced the launch of Apollotm for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital ...

Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the ...